Mark Fladrich has taken over the position of chief commercial officer at the Grünenthal Group and now is responsible for the entire global commercial organization. Fladrich was area VP, Southern and Western Europe, at AstraZeneca, based in the United Kingdom. He joins Grünenthal effective Sept. 1, 2017.
Fladrich has almost 30 years of experience in the pharmaceutical industry, and more than 20 years at AstraZeneca. Executives say the 57-year-old Australian by nationality brings a broad variety of expertise to Grünenthal — from in-market knowledge to regional and global sales and marketing. Key highlights include large country management roles in Germany as well as more recently in Australia and New Zealand with more than $1 billion of sales revenue in each country. He also was globally responsible for all Phase III products and promoted brands and for commercial input into R&D for all stages of clinical development.
In his role as chief commercial officer at Grünenthal, Fladrich will lead the entire global commercial organization. Executives say the aspiration is to bring global commercial closer to the markets, further accelerate launch readiness, and integrate the business with stronger strategic input into R&D.
“We are delighted to welcome Mark Fladrich as new member of the corporate executive board,” says Gabriel Baertschi, CEO of Grünenthal. “With Mark in the team, we gain an experienced and passionate commercial leader with strong business expertise, entrepreneurial spirit and track record in working closely with a R&D organization.
“We are confident that together with him we will successfully lead Grünenthal towards our ambition: deliver four to five new products to patients in diseases with high unmet needs and reach revenues of €2 billion by 2022.”
The Grünenthal Group is an entrepreneurial, science-based pharmaceutical company specialized in pain, gout, and inflammation. Grünenthal is an independent, family-owned company headquartered in Aachen, Germany.